


Slide 1



**Platelets:
Purpose, Pictures
plus
Problems**

Slide 2

Objectives


1. Review the basic function of platelets
2. Exam the 3 stages of platelet function
3. Take an in depth look at several disease states involving platelets
4. Review case studies involving platelet abnormalities

Slide 3


Platelets – The Basics

- Also called thrombocytes
- Biconvex discoid shaped
- Cytoplasmic fragments of a megakaryocyte
- 1/3 the size of a normal erythrocyte with a ratio of platelet to red blood cell approx. 1:15
- Shed in the bone marrow and found in the peripheral blood

Slide 4



Slide 5




Slide 6


Breaking it Down

- Peripheral Zone
 - Rich in glycoproteins required for adhesion, activation and aggregation
- Sol-gel Zone
 - Rich in microtubules and microfilaments allowing platelets to maintain the discoid shape
- Organelle Zone
 - Rich in platelet granules
 - Alpha - contain clotting mediators - Factors V, VIII, Fibrinogen
 - Delta - also called "dense bodies" contain ADP, calcium & serotonin
- Membranous Zone
 - Endoplasmic reticulum-derived membranes organized into a dense tubular system responsible for thromboxane A2 synthesis


Slide 7



Slide 8



Slide 9



Slide 10

Platelet Dynamics
IT'S COMPLICATED


- **193** proteins and **301** interactions are involved
- Three stages – Adhesion, Activation, Aggregation
- These stages occur in rapid succession and each continues until the trigger for that stage is no longer present – lots of overlap!!

Slide 11

Super Simplified

- **Adhesion** - Platelets attach to the outside of the interrupted endothelium
 - When an endothelial layer is disrupted, collagen and vWF anchor platelets to the sub-endothelium.
 - Platelet GPIIb-IX-V receptor binds with vWF and GPIIb receptor binds with collagen
- **Activation** - Platelets change shape, turn on receptors & secrete chemical messages
 - Occurs seconds after adhesion starts
 - Activated platelets secrete the contents of their granules through their canalicular systems to the exterior
 - Morphology of platelet changes and becomes "sticky"
- **Aggregation** - Platelets connect to each other through receptor bridges
 - Occurs minutes after activation starts
 - Shape changes from curled to straight and becomes capable of binding

Slide 12



Slide 13

Platelet Disorders

- There are several things that can cause problems
 - **Thrombocytopenia** - Not enough
 - **Thrombocytosis**- Too many
 - **Dysfunctional** – Not working correctly

Slide 14

Thrombocytopenia – Not Enough

- Immune Thrombocytopenic purpura (ITP)
- Thrombotic Thrombocytopenic purpura (TTP)
- Chemotherapy induced
- Splenomegaly
- Drug induced
- Aplastic anemia
- Pregnancy associated
- Babesiosis
- Pseudothrombocytopenia
- **And it goes on and on and on**

Slide 15

Thrombocytosis – Too Many

Reactive

- Chronic infection
- Chronic inflammation
- Malignancy
- Post splenectomy
- Iron deficiency
- Acute blood loss

Myeloproliferative neoplasms
(platelets elevated and dysfunctional)

- Essential thrombocytosis
- Polycythemia vera
- Congenital
- Associated with other myeloid neoplasms

Slide 16

Dysfunctional – Not Working

Congenital

- Bernard-Soulier Syndrome – adhesion disorder
- Hermansky-Pudlak Syndrome – activation disorder
- Wiskott-Aldrich Syndrome – aggregation disorder
- Plus many, many more ...
 - Granule amount and release disorder
 - ADP receptor defect
 - Storage pool defects

Acquired

- PNH (Paroxysmal Nocturnal Hemoglobinuria)
- Asthma
- Cancer
- Samter's Triad (aspirin exacerbated respiratory disease)


Slide 17

Drugs and Platelets

Different drugs affect platelet function in various ways

Some Drugs


- **Suppress Platelet Function**
 - Aspirin
 - Clopidogrel (Plavix)
 - Clostazol



Some Drugs

- **Stimulate Platelet Production**
 - Thrombopoietin mimetics
 - Desmopressin
 - Factor VIIa


Slide 18



Aspirin – Just for a Minute

- Aspirin **irreversibly** disrupts platelet function by inhibiting cyclooxygenase -1 (COX-1) thus preventing normal hemostasis
- Platelets in the presence of aspirin are unable to produce new cyclooxygenase which is needed in order for platelets to aggregate
- Normal platelet function will not return until the use of aspirin has ceased and old platelets are replaced with new ones that haven't been exposed to aspirin
- Time to return to normal function after discontinuing use of aspirin is about one week


Slide 19

 Symptoms of Platelet Disorders

- Excessive bleeding
- Spontaneous bleeding
- Petechiae
- Purpura
- Bleeding gums
- Nose bleed
- G.I. bleed
- Menorrhagia
- Intracranial bleeding
- Thrombosis

Slide 20

Pictures to Ponder




Petechiae

Purpura

Slide 21


Pictures to Ponder




Purpura

Looks like a rash

Slide 22



Slide 23




Slide 24

Disorders to Review in More Detail

- ITP – Immune Thrombocytopenic Purpura
- TTP – Thrombotic Thrombocytopenic Purpura
- CIT – Chemotherapy Induced Thrombocytopenia
- Thrombocytosis in Iron Deficiency Anemia
- Polycythemia Vera
- Bernard-Soulier Syndrome

Slide 25



ITP
Immune
Thrombocytopenic
Purpura

Slide 26


Taking a Closer Look at ITP

- Immune (Idiopathic) Thrombocytopenic Purpura
 - Autoimmune disorder resulting in thrombocytopenia
 - Etiology unknown
 - Acute infection may trigger

Slide 27

In Addition with ITP

- Increased prevalence in people with systemic autoimmune diseases such as Rheumatoid arthritis and systemic lupus (SLE)
- Genetic component suspected to predispose



Slide 28

ITP – The Mechanism

- Complex, unbalanced immune response
- Antibodies attach to platelet surface-membrane glycoproteins
- Macrophages are highly stimulated which adds to the efficient binding of the coated platelets

Slide 29

ITP – The Mechanism

- Platelets bound by these antibodies contain the FC region of the antibody
- Platelets are cleared by FcγR-bearing macrophages
- Occurs in the reticuloendothelial system, specifically the monocytic - phagocytic cells in the spleen

Slide 30

A Picture Tells the Story


• Picture of antibody bound platelet plus macrophage

• Platelet opsonization occurs = decreased platelets


• And an interesting aside, platelet production may also be decreased in some cases

From: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC111115/>


Slide 31




Slide 32



Slide 33



Slide 34



TTP
Thrombotic
Thrombocytopenic
Purpura

Slide 35

TTP – What's the Difference

- Thrombotic Thrombocytopenic Purpura
 - Thrombotic microangiopathy
 - Platelet consumption resulting in thrombocytopenia
 - Rare disease – only 6 cases per million per year – most acquired but rare congenital
 - Occurs when there is an ADAMTS13 deficiency
 - Autoimmune disease – development of inhibitory antibodies to ADAMTS13
 - ADAMTS13 = A Disintegrin And Metalloproteinase with Thrombospondin type 1 motif, member 13
- Acute, life threatening disease that is a medical emergency


Symptoms

- Thrombocytopenia
- Hemolytic anemia
- Confusion
- Headaches
- Visual problems
- Renal impairment
- Fever

← Let's talk about this

Slide 36


RBCs Forced to Travel in Narrowed Vessel
Red Cells may BURST going through



Platelet Plug

Red Cells

Slide 37




Slide 38

TTP in Layman's Terms

- VWF (VonWillebrand's Factor) is a multimeric plasma glycoprotein. It recruits platelets to the site of vessel injury.
- VWF multimeric size directly relates to its hemostatical activity
 - The larger it is the more hypercoagulability the VWF multimer
- Regulation of the VWF size is controlled by ADAMTS13
- Deficiency in ADAMTS13 allows VWF multimer to increase in size and in hyperactivity
- Results are unwanted platelet aggregation and platelet rich thrombus formation

Slide 39




Slide 40

Treatment for TTP


- First line treatment for TTP is plasma exchange
- Plasma exchange removes circulating ADAMTS13 autoantibodies and provides a fresh source of ADAMTS13
- Decreases mortality from 90% down to 10%
- During crisis – patient undergoes plasma exchange 2-3 times a day until stable and then once a day until the 2nd day after platelet count is back to normal
- Continued exchange every 3-4 weeks to prevent relapse

Slide 41

Treatment for TTP

- ADAMTS13
 - No natural inhibitor
 - Long plasma half-life
 - Relatively low levels required to keep VWF multimers in check
- Immunosuppression drugs 
 - Used to combat autoimmune aspect of the disease
 - Stops immune system from making more antibodies !

Slide 42

CIT 
**Chemotherapy
Induced
Thrombocytopenia**

Slide 43

Chemotherapy Induced Thrombocytopenia

- Chemotherapy-induced thrombocytopenia (CIT) is a common hematologic side effect of both myelosuppressive and ablative therapy
- Runs the risk of life-threatening spontaneous hemorrhage
- CIT necessitates reduction or delays in chemo treatment
 - However
 - Dose and time schedule of chemo drug is scientifically derived to produce the best chance of survival or cure
 - When dose of therapy is reduced or treatment cycles prolonged, cure rates are lowered


Slide 44

What Causes CIT?

- **Chemotherapy works by killing rapid growing cancer cells**
 - Hematopoietic progenitor cells are also rapid growing cells
 - Chemotherapy interferes with cell production in the bone marrow
- **Thrombopoietin is the primary regulator of thrombopoiesis**
 - Promotes megakaryocyte differentiation from stem cells
 - Works in conjunction with other cytokines including interleukin
- **Interaction between megakaryocytes and bone marrow stromal components are critical for platelet production**
 - Chemotherapy results in myeloablation of the marrow stroma
 - Megakaryocytes cannot be produced until the hematopoietic tissue bed repairs and reconstitutes


Slide 45

Treatment for CIT



- Most common treatment is platelet transfusion
- Transfusions are a *temporary fix* until the bone marrow can start producing platelets on its own
- Dose reduction of chemotherapy or holding chemotherapy will allow the marrow to recover more quickly
- Growth factor drugs used to stimulate production
 - Romiplostim (Nplate)
 - Eltrombopag (Promacta)

Slide 46



Slide 47

Thrombocytosis in Iron Deficiency


- Iron Deficiency is the leading cause of anemia
- Microcytic-hypochromic iron deficiency anemia impairs oxygen delivery to the tissues
- Iron deficiency anemia has lower numbers of circulating red cells - less cells to carry the oxygen

Slide 48

Thrombocytosis in Iron Deficiency

- Receptor cells in the kidneys detect low O₂ levels
- Kidneys respond by increased secretion of erythropoietin into the blood
- Erythropoietin causes the proerythroblasts in the bone marrow to mature more quickly

But what does this have to do with platelets ?



Slide 49

Thrombocytosis in Fe Deficiency
Side effects of Erythropoietin in bone marrow

- There is a degree of homology in the amino acid sequence in erythropoietin and thrombopoietin (the hormone that stimulates platelets)
- This results in stimulation of the megakaryoblasts by the erythropoietin resulting in an increased production of platelets

Slide 50

Thrombocytosis in Fe Deficiency

- **Reactive Thrombocytosis occurs**
 - The greater the degree of iron deficiency the greater the degree of thrombocytosis
 - Increased chance of thrombosis – can be life threatening
- **Vice Versa**
 - Treatment of the iron deficiency reduces the thrombocytosis, reduces the chance of a thromboembolic event

Slide 51


From Stem Cell to Mature Blood Cells

There is a degree of homology in the amino acid sequence in erythropoietin & thrombopoietin


The erythropoietin stimulates the progenitor cell to produce more RBCs

Side effect is that more platelet are also produced

Slide 52



Slide 53



Slide 54

Polycythemia Vera (PCV)

- Also known as erythremia
- Neoplasm in which bone marrow produces too many RBCs
- Also, results in overproduction of WBCs and platelets
- Most common in the elderly

Slide 55

Signs of PCV

- Itching
- Pain in hands and feet
- Bluish coloration of skin
- Gout-like type of arthritis
- Peptic ulcers
- Headache

More severe PCV can result in:

- Heart attack
- Stroke
- DVT's

Slide 56

PCV Mechanism

- Results from a mutation occurring in tyrosine kinase
 - Janus Kinase family – JAK2 (V617F)
- Erythroid precursors become hypersensitive to erythropoietin


Very little erythropoietin causes mass production of RBCs. Also results in over production of platelets!

Slide 57


PCV Mechanism

- Results from a mutation occurring in tyrosine kinase
 - Janus Kinase family – JAK2 (V617F)
- Results in erythroid precursors being hypersensitive to erythropoietin
 - Very little erythropoietin causes mass production of RBCs. Also results in over production of platelets.
- Essential thrombocythemia
 - Increase in platelet "stickiness"
 - Tiny blood clots in vessels of extremities
 - High volume of blood causes sluggish flow – giving more time for platelets to get "stuck"

Slide 58



Slide 59




Slide 60


Treatment of PCV

- Chronic disease – no cure
- Untreated cases may be fatal
- Need to treat the symptoms
 - *Therapeutic phlebotomy*
 - Decreases the number of circulating RBCs
 - *Aspirin therapy*
 - Decreases the platelets ability to “stick”
 - *Interferon*
 - *Chemotherapy*
 - Hydroxyurea – with caution
 - Leads to increased risk of converting to Acute Myelogenous Leukemia (AML)


Slide 61




Slide 62



Slide 63




Slide 64



Slide 65


- Signs /Symptoms in Bernard-Soulier
- Pre and postoperative bleeding
 - Bleeding gums
 - Easy bruising
 - Heavy menstrual periods
 - Nosebleeds
 - Prolonged bleeding from small cuts
 - Decreased platelet counts (20,000 – 100,000)
 - Large and giant platelets on peripheral smear
 - Often misdiagnosed

Slide 66




Slide 67

Treatment for BSS

- No cure – but can have quality of life
- Therapeutic approaches to general and specific treatment of bleeding episodes
- Patients should avoid aspirin products 


Slide 68

Treatment for BSS


- Blood and platelet transfusions used when severe bleeding occurs 
- Desmopressin found to decrease bleeding times
- Bone marrow or stem cell transplantation in extreme cases

Slide 69

Platelet Count Testing



Slide 70



Slide 71

Expanded Platelet Count Testing

Fluorescent Platelet Count

- Done whenever platelet count is 50,000 or below or when specifically requested by the physician
- Added benefit is
 - Immature Platelet Fraction (IPF)

IPF CPT CODE 85055

Slide 72

Immature Platelet Fraction (IPF)


- IPF is a measure of immature platelets in the circulating blood
- An increased IPF with thrombocytopenia may indicate:
 - Peripheral destruction or consumption of platelets such as:
 - Idiopathic thrombocytopenia (ITP)
 - Thrombotic thrombocytopenic purpura (TTP)
 - Disseminated intravascular coagulation (DIC)

Slide 73

Immature Platelet Fraction (IPF)

- Monitor marrow recovery post chemotherapy
- Platelets are killed off by chemotherapy drugs
- In bone marrow recovery, platelets are produced to resupply the peripheral blood
- When platelets are needed in the blood, immature platelets are released early from the marrow
- **A high IPF post chemotherapy is a good indication that platelets are being produced**

Slide 74



Slide 75

Examples of Canned Text Comments for Platelets and IPF

Fluorescent Platelets

- Platelet count obtained by Fluorescent Flow Cytometry methodology which is specific for Platelet Mitochondria, providing the most accurate enumeration

Immature Platelet Fraction

- An elevated immature Platelet Fraction indicates platelets are being produced
- A low platelet and low IPF is consistent with a platelet production disorder


Slide 76

Case Studies

Finally,
What You've Been Waiting For
!

Slide 77

Fall in Michigan



Slide 78

Case #1 Fall in Platelets

48 year old married man with twin 14 year old sons is diagnosed with Pancreatic Cancer - Dx 157.0. He has no family history of cancer of any kind; he presented with upper abdominal pain - his an ulcer. CT scan showed a mass on the head of the pancreas and biopsy confirmed adenocarcinoma. Patient is going through first line treatment with Gemtastabine (Gemzar). Treatment plan is 7 cycles of Gemzar and there is a check of labs and CA19-9 tumor marker.

Note: A cycle is three weeks long. Chemotherapy drug is given on day one and on day eight. In addition, laboratory work, including a CBC is done on these days. No drug is given on day fifteen but the patient presents for lab tests and a nurse evaluation.

Weekly CBC's are drawn to make sure blood counts are within range so drug can be given safely.

Baseline CBC obtained: Cycle 1 - Day 1

WBC, RBC, and PLT all within normal range, the HGB is slightly decreased

| COMPLETE BLOOD COUNT - rml | | units | Ordered by: 001 | |
|----------------------------|---|-------|----------------------|--------------|
| WBC | Ⓢ | 15.3 | x10 ³ /μL | 4.0 - 11.0 |
| RBC | Ⓢ | 4.48 | x10 ⁶ /μL | 4.20 - 6.00 |
| HGB | Ⓢ | 13.1 | g/dL | 13.5 - 18.0 |
| HCT | Ⓢ | 37.7 | % | 40.0 - 52.0 |
| MCV | Ⓢ | 84.3 | fL | 89.0 - 107.0 |
| MCH | Ⓢ | 29.2 | pg | 27.0 - 33.4 |
| MCHC | Ⓢ | 34.7 | g/dL | 32.5 - 35.5 |
| PLAT | Ⓢ | 205 | x10 ³ /μL | 130 - 400 |

First and second cycles go smoothly, no issues or complications.

Slide 79

Cycle 3 - Day 1

- Platelet count has dropped to 92,000
- RBC and HGB are also slightly decreased
- WBC is within normal range

COMPLETE BLOOD COUNT - Final edit Ordered by: 017

| | | | |
|------|----------|----------------------|-------------|
| WBC | 4.0 | x10 ³ /µl | 4.0 - 11.0 |
| RBC | 4.06 low | x10 ⁶ /µl | 4.20 - 6.00 |
| HGB | 12.6 low | g/dL | 13.5 - 18.0 |
| HCT | 36.3 low | % | 40.0 - 52.0 |
| MCV | 84.0 | fL | 82.0 - 97.0 |
| MCH | 28.9 | pg | 27.0 - 33.4 |
| MCHC | 34.2 | g/dL | 32.5 - 35.5 |
| Plat | 92 low | x10 ³ /µl | 130 - 400 |

Slide 80

Cycle 3 - Day 8

- Platelet count has dropped to 42,000
- Fluorescent platelet is reflexed
- IPF is 0
- WBC, RBC and HGB are also low

COMPLETE BLOOD COUNT - Final edit Ordered by: 017

| | | | |
|------|----------|----------------------|-------------|
| WBC | 2.8 low | x10 ³ /µl | 4.0 - 11.0 |
| RBC | 3.97 low | x10 ⁶ /µl | 4.20 - 6.00 |
| HGB | 10.9 low | g/dL | 13.5 - 18.0 |
| HCT | 30.6 low | % | 40.0 - 52.0 |
| MCV | 83.9 | fL | 82.0 - 97.0 |
| MCH | 28.6 | pg | 27.0 - 33.4 |
| MCHC | 33.4 | g/dL | 32.5 - 35.5 |
| Plat | 42 low | x10 ³ /µl | 130 - 400 |

pl^t count obtained by Fluorescent Flow Cytometry which is specific for platelet mitochondria, the most accurate enumeration methodology

IMMATURE PLATELET FRACTION TEST - Final edit Ordered by: 017

| | | | |
|----------------------------|---------|---|-----------|
| IMMATURE PLATELET FRACTION | 0.0 low | % | 0.0 - 7.0 |
|----------------------------|---------|---|-----------|

Slide 81


Action Taken

- Patient's nurse reports the IPF of 0 to the physician
- Physician orders a repeat platelet count for the next day
- Patient is given instructions not to shave and to call if he has a nose, gum or any other type of bleed
- Patient returns in the morning for the repeat CBC; platelet count is 6 and IPF is still 0
- Patient receives 2 units of platelets

Slide 85

Marked Platelet Clumping on Slide Review

- Platelet Count from analyzer = 8,000
- But look what is on the slide?????



A circular microscopic image showing a dense cluster of small, dark, irregularly shaped platelets that have clumped together, illustrating the phenomenon of platelet clumping.

Slide 86

Summary - Pseudothrombocytopenia

- CBC was repeated with collection in a Na Citrate tube in place of the traditional EDTA tube
- Platelet count from the Na Citrate tube = 278,000
- Pseudothrombocytopenia also called spurious thrombocytopenia
- Phenomenon caused by in vitro agglutination of platelets
- Primary causes for this phenomenon
 - EDTA anticoagulant
 - Cold Agglutinins
 - Multiple Myeloma

Slide 87

Case #3 Unexplained Blood Clot

- A 39 year old female presents with a blood clot in her leg
- Patient has a history of iron deficiency due to heavy menorrhagia
- Patient also claims to have bleeding episodes between periods
- Patient takes a minimal dose of oral iron due to problems with constipation when taking increased dose of iron supplements
- History of iron therapy & blood transfusions due to anemia
- Full hematology work up done in office including CBC, Ferritin and Iron/Iron binding


Slide 88

| CBC Results | | | | |
|---|------|----------------------------|----------------------|-------------|
| COMPLETE BLOOD COUNT - Final edit Ordered by: 017 | | | | |
| WBC | 5.07 | | x10 ³ /µl | 4.0 - 11.0 |
| RBC | 3.73 | | x10 ⁶ /µl | 3.90 - 5.20 |
| HGB | 5.8 | ← WCV - that's legit! | g/dL | 12.0 - 16.0 |
| HCT | 24.2 | | % | 35.0 - 47.0 |
| MCV | 62.9 | | fL | 82.0 - 97.0 |
| MCH | 18.8 | | pg | 27.0 - 33.4 |
| MCHC | 28.9 | | g/dL | 32.5 - 35.5 |
| Plat | 646 | ← But what's up with this? | 10 ³ /µL | 130 - 400 |
| Neut% | 52.7 | | % | 38 - 70 |
| Lymph% | 33.1 | | % | 20 - 45 |
| MONO% | 8.9 | | % | 2 - 14 |
| EOS% | 3.9 | | % | 0 - 5 |
| Baso% | 1.2 | | % | 0 - 2 |
| Immature Gran % | 0.7 | | % | |
| Nucleated RBC % | 0.0 | | % | <1 |

Slide 89

| Result | Value (Previous) | Units | Range |
|---|------------------|-------|------------|
| FERRITIN - Final Ordered by: 030 | | | |
| Ferritin | <5.0 | Ng/mL | 10 - 120 |
| IRON/IRON BINDING - Final Ordered by: 030 | | | |
| IRON | 12 | ug/dl | 37 - 145 |
| TIBC | 441 | ug/dl | 250 - 400 |
| Iron Sat Percent | 3 | % | 15 - 50 |
| VITAMIN B12 / FOLATE - Final Ordered by: 030 | | | |
| B12 | 452 | pg/ml | 200 - 1100 |
| Folate | 10.1 | Ng/mL | 0 - 20 |

Slide 90



Slide 91

Follow Up

- Significant anemia consistent with iron deficiency
- 2 units of PRBCs given
- Strongly recommend a GYN consultation for possible hysterectomy
- Injectafer[®] to be given in 1 week
- Recheck CBC in 2 weeks
- Note: IPF is normal at 2.4%

Slide 92

Two Weeks Later

Hemoglobin goes up and platelet count goes down

| RESULTS | Q1515 | PO | OR | #000 | Ordered by: 030 |
|--------------------------|-------|------------------------|----|----------------------|-----------------|
| WBC | 5.1 | | | x10 ³ /dL | 4.0 - 11.0 |
| % Neutrophils | 59 | | | % | |
| % Bands | 0 | | | % | |
| RBC | 3.69 | ← High going up | | x10 ⁶ /dL | 3.90 - 5.20 |
| HGB | 6.9 | | | g/dL | 12.0 - 16.0 |
| RESULTS Q1515 PO OR #000 | | | | | |
| Lymphocytes | 30 | | | % | |
| Monocytes | 6 | | | % | |
| HCT | 24.0 | | | % | 36.0 - 47.0 |
| MCV | 65.0 | | | fL | 82.0 - 97.0 |
| Basophils | 2 | | | % | |
| Eosinophils | 3 | | | % | |
| MCH | 10.7 | | | pg | 27.0 - 33.4 |
| MCHC | 16.8 | | | g/dL | 32.5 - 35.5 |
| Atypical Lymphs | 0 | | | % | |
| Retenulocytes | 0 | | | % | |
| Plat | 520 | ← Platelets going down | | /mm ³ | 130 - 400 |

Slide 93

Case #4 Unexplained Thrombocytopenia

- A 29 year old woman presents with bruising and petechiae
- Patient states recent viral illness
- Past history of thrombocytopenia, age 2, attributed to ITP
- LDH is slightly elevated at 420 U/L
- Initial CBC reveals platelet count of 14,000 and IPF of 46%
- IPF indicates bone marrow is working – not a production problem

Slide 94

The Results

COMPLETE BLOOD COUNT - Final edit Ordered by: 017

| | | | | | |
|------|---|------|-----------------|--------------------|-------------|
| WBC | Ⓢ | 12.7 | ¹⁰ 3 | ¹⁰ 9/ul | 4.0 - 11.0 |
| RBC | Ⓢ | 3.33 | | ¹⁰ 6/ul | 3.90 - 5.20 |
| HGB | Ⓢ | 10.4 | | g/dL | 12.0 - 16.0 |
| HCT | Ⓢ | 32.0 | | % | 36.0 - 47.0 |
| MCV | Ⓢ | 99.1 | | fL | 82.0 - 97.0 |
| MCH | Ⓢ | 30.3 | | pg | 27.0 - 33.4 |
| MCHC | Ⓢ | 30.6 | | g/dL | 32.5 - 35.5 |
| Plat | Ⓢ | 14 | | ¹⁰ 3/ul | 130 - 400 |

Way too low

Platelet count obtained by Fluorescent Flow Cytometry methodology which is specific for Platelet Mitochondria, providing the most accurate enumeration.

| | | | | | |
|-----------------|---|------|--|---|---------|
| Neut% | Ⓢ | 61.5 | | % | 38 - 70 |
| Lymph% | Ⓢ | 0.18 | | % | 20 - 42 |
| MONO% | Ⓢ | 0.02 | | % | 2 - 14 |
| EOS% | Ⓢ | 0.01 | | % | 0 - 5 |
| BAASO% | Ⓢ | 0.00 | | % | 0 - 2 |
| Immature Gran % | Ⓢ | 0.00 | | % | <1 |
| Nucleated RBC % | Ⓢ | 0.0 | | % | <1 |

Not working had to make more

IMMATURE PLATELET FRACTION TEST - Final edit Ordered by: 017

| | | | | | |
|----------------------------|---|----|--|---|-----------|
| IMMATURE PLATELET FRACTION | Ⓢ | 46 | | % | 0.9 - 7.0 |
|----------------------------|---|----|--|---|-----------|

AN ELEVATED IMMATURE PLATELET FRACTION INDICATES PLATELETS ARE BEING PRODUCED

Slide 95

- Diagnosis and Treatment**
- Recurrence of ITP
 - Critically low platelet count along with very high IPF – common findings in ITP
 - Initial therapy was 1 mg/kg dosing of prednisone
 - After no significant improvement in 48 hours, IVIG was added with a 1g/kg x2 day course
 - Platelet count responded appropriately and count increased to 114,000
 - Patient to continue on 90 mg prednisone and weekly CBC checks

Slide 96

5 Days Later - Following Treatment

COMPLETE BLOOD COUNT - Final edit Ordered by: 017

| | | | | | |
|------|---|------|--|--------------------|-------------|
| WBC | Ⓢ | 6.56 | | ¹⁰ 3/ul | 4.0 - 11.0 |
| RBC | Ⓢ | 3.86 | | ¹⁰ 6/ul | 3.90 - 5.20 |
| HGB | Ⓢ | 10.9 | | g/dL | 12.0 - 16.0 |
| HCT | Ⓢ | 34.3 | | % | 36.0 - 47.0 |
| MCV | Ⓢ | 98.7 | | fL | 82.0 - 97.0 |
| MCH | Ⓢ | 31.2 | | pg | 27.0 - 33.4 |
| MCHC | Ⓢ | 32.0 | | g/dL | 32.5 - 35.5 |
| Plat | Ⓢ | 114 | | ¹⁰ 3/ul | 130 - 400 |

Much better

| | | | | | |
|-----------------|---|------|--|---|---------|
| Neut% | Ⓢ | 6.27 | | % | 38 - 70 |
| Lymph% | Ⓢ | 0.15 | | % | 20 - 42 |
| MONO% | Ⓢ | 0.09 | | % | 2 - 14 |
| EOS% | Ⓢ | 0.01 | | % | 0 - 5 |
| BAASO% | Ⓢ | 0.00 | | % | 0 - 2 |
| Immature Gran % | Ⓢ | 0.00 | | % | <1 |
| Nucleated RBC % | Ⓢ | 0.00 | | % | <1 |

Still working but not as hard

IMMATURE PLATELET FRACTION TEST - Final edit Ordered by: 017

| | | | | | |
|----------------------------|---|----|--|---|-----------|
| IMMATURE PLATELET FRACTION | Ⓢ | 17 | | % | 0.9 - 7.0 |
|----------------------------|---|----|--|---|-----------|

Slide 97

Case # 5 **Low Hemoglobin – High Platelets**

- 41 year old male presented to the clinic with splenomegaly related to his history of severe anemia due to pyruvate kinase deficiency

PK deficiency is an inherited metabolic disorder of the enzyme pyruvate kinase. This enzyme is essential in glycolysis for ATP production in the RBC.
Without pyruvate kinase, RBCs cannot synthesize ATP & cellular death occurs by dehydration at the cellular level

- The patient routinely has Hgb levels of 6-7g/dl
- He has not been under the care of a physician for several years

Slide 98

- Additional symptom includes abdominal pain due to splenic infarcts
- Hgb low at 6.3 and platelet count high at 489
- Remember the cross over effect of erythropoietin?

COMPLETE BLOOD COUNT -Final edit Ordered by: 02.

| | | | |
|------|---|-------|------|
| WBC | ? | 6.1 | |
| RBC | ? | 1.98 | Low |
| HGB | ? | 6.3 | Low |
| HCT | ? | 19.4 | Low |
| MCV | ? | 110.6 | High |
| MCH | ? | 34.8 | High |
| MCHC | ? | 31.0 | Low |
| Plat | ? | 489 | High |

Note the high platelet count

Slide 99

- Patient receives two units of packed RBCs and is scheduled for follow up care and weekly CBCs
- CBC repeated at return visit: Hgb is 8.5 but platelets are crazy high – **over a million**

| Result | 7/9/2015 11:24:00 AM | 6/22/2015 10:21:00 AM | 6/16/2015 8:06:00 AM |
|--------------------|----------------------------|-----------------------------|----------------------------|
| *** Hematology *** | | | |
| WBC | 14.8 | 6.1 | 6.3 |
| ANC | 10.2 | 4.1 | 4.1 |
| RBC | 2.71 | 2.66 | 2.03 |
| HGB | 8.5 | 9.0 | 7.0 |
| HCT | 26.0 | 27.3 | 22.3 |
| MCV | 95.9 | 102.6 | 109.9 |
| MCH | 31.4 | 33.8 | 34.5 |
| MCHC | 32.7 | 33.0 | 31.4 |
| Plat | 1325 | 433 | 466 |

WOW

Slide 100

What are Those High Platelets From?

- Critical high platelet count reported to physician
- Physician informs the tech that the patient had a splenectomy the previous week
- The spleen plays a major role in platelet regulation as the primary site of destruction of platelets
- Reactive thrombocytosis is a predictable finding after a splenectomy with platelet counts peaking at 1- 3 weeks and returning to normal after approx. one month

Slide 101


Case #6 Tooth Extraction Complication?

- 48 year old woman reports to the ED with complaints of generalized weakness with increased intensity over the past week
- Patient states she has visual changes in her right eye
- History includes recent tooth extraction (two weeks prior) followed by antibiotic therapy to ward off infection
- Patient has increased bruising, bloody nose and persistent blood clots along with bleeding in her mouth
- Complains of dyspnea on exertion and chills on and off for the past month

Slide 102

Ultrasound and Lab Work Done

- Ultrasound shows blood clot in her retinal vein



- Lab work done including a CBC

Slide 103


| Pancytopenia Bone Marrow Production Problem | | | |
|--|----------|--|-----------|
| WBC | 0 (1.7) | $10^3/\mu\text{L}$ | 4-11 |
| ANC | 0 (0.3) | $10^3/\text{mm}^3$ | 1.5-7.7 |
| RBC | 0 (1.84) | $10^9/\mu\text{L}$ | 3.9-5.2 |
| HGB | 0 (3.3) | g/dL | 12-16 |
| HCT | 0 (10.1) | % | 36-47 |
| MCV | 0 (64) | fL | 82-97 |
| MCH | 0 (17.9) | g/dL | 27-33.4 |
| MCHC | 0 (32.6) | g/dL | 32.5-35.5 |
| Plat | 0 (1) | varies | 130-400 |
| IMMATURE PLATELET FRACTION | 0 (0.0) | Indicates Bone Marrow Production Problem | |

Slide 104


The Follow-up

- Patient was transfused with both RBCs and Platelets
- Hematology consultation ordered, including bone marrow biopsy
- Bone marrow result was notable for *aplastic anemia*
- Multiple blood and platelet transfusions did not improve her blood counts
- Patient was put on cyclosporine (immunosuppressive therapy) along with prednisone (steroid therapy)
- *Did the complications and medication from the tooth extraction cause the aplastic anemia?*


Slide 105




Slide 106



Slide 107



Slide 108



Slide 109

Summary and Conclusion

- Retinal clot most likely due to complications from the tooth extraction
- Shortness of breath & chills were present for over a month but dental work occurred only two weeks before ED visit
- Aplastic anemia was likely already present
- The aplastic anemia resulted in decreased platelet production, making it difficult for healing at the site of the tooth extraction


Slide 110

Case #7 Blast from the past - 2009

- 19 year old female presents to the ED with a headache, nausea, vomiting, fatigue and confusion
- CBC reveals HGB = 5.8g/dl and platelet count = 1,000
- Patient was jaundiced and bilirubin was 4.4 mg/dl
- Blood smear showed microspherocytes and schistocytes
- Coombs test was negative
- Bone Marrow biopsy was performed
- Clinical diagnosis of TTP

Slide 111

Under the Microscope
no platelets along with
Schistocytes and Spherocytes



RBCs bursting when trying to get passed the platelet plug

Presence of schistocytes suggest thrombotic microangiopathy

Slide 115

Here We Go Again

| COMPLETE BLOOD COUNT - Final <small>Unit</small> <small>Ordered by: 01Z</small> | | | |
|---|------|----------------------------------|-------------|
| WBC | 16.1 | 10 ³ /mm ³ | 4.0 - 11.0 |
| RBC | 2.17 | 10 ⁶ /mm ³ | 3.90 - 5.20 |
| HGB | 6.4 | g/dL | 12.0 - 16.0 |
| HCT | 20.8 | % | 35.0 - 47.0 |
| MCV | 92.6 | fL | 82.0 - 97.0 |
| MCH | 29.4 | pg | 27.0 - 33.4 |
| MCHC | 31.8 | g/dL | 32.0 - 36.0 |
| Plat | 9 | 10 ³ /mm ³ | 130 - 400 |

Platelet count obtained by Fluorescent Flow Cytometry methodology which is specific for Platelet Microbeads, providing the most accurate enumeration.

| | | | |
|-----------------|------|---|---------|
| Neut% | 49.5 | % | 38 - 70 |
| Lymph% | 36.0 | % | 20 - 45 |
| MONO% | 12.3 | % | 2 - 14 |
| EOS% | 1.8 | % | 0 - 5 |
| Baso% | 0.2 | % | 0 - 2 |
| Immature Gran % | 0.2 | % | <1 |
| Nucleated RBC % | 0.0 | % | <1 |

| IMMATURE PLATELET FRACTION TEST - Final <small>Unit</small> <small>Ordered by: 01Z</small> | | | |
|--|----|---|-----------|
| IMMATURE PLATELET FRACTION | 19 | % | 0.9 - 7.0 |

An elevated immature platelet fraction indicates platelets are being produced

Slide 116

Moving Too Fast

- Patient begins daily plasmapheresis x2/day
- TTP is a high risk factor in pregnancy (patient has already had two miscarriages)
- Due to complications, baby is delivered by cesarean section at 24 weeks
- Baby boy is born measuring 11" long and weighing only 1lb 6oz. Baby is admitted to NICU.
- Mom continues to have plasmapheresis after delivery as her life is still in danger. Tapered down to 3 times weekly once platelet count started to recover.
- Mom's platelet count returns to normal, Platelet = 296,000
- At 5 weeks, baby boy is stable and up to 1lb 12oz


Slide 117

Happy Ending

Slide 118



Slide 119



Slide 120

- Summing it Up
- Platelets play a vital role in the clotting cascade
 - Platelet dynamics are complicated
 - Platelets have three functions; adhesion, activation and aggregation
 - Issues can occur when there are too few, too many or dysfunctional platelet
 - Platelet disorders are numerous and can be serious, even life-threatening
 - Case studies involving platelet abnormalities provide a good source for education

References

- Platelet adhesion/aggregation/activation; Pathology, Pharmacology, Physiology, 09/25/12 usmle, 287
- Immune Thrombocytopenic Purpura (ITP); Fikri Abdullah Zawawi, Kathryn Kaniasan; Health and Medicine 11-13-16
- A NAC for TTP; Lou, K-J Sci BX4(8); 10.1038/scibx.2011.214
- Bernard-Soulier Syndrome (Hemorrhagic purpura thrombocytopenic); Orphanet Journal of Rare Diseases, 2006. Lanza; licensee BioMed Central Ltd.; <https://doi.org/10.1186/1750-1172-1-46>
- Retinal vein occlusion; Addenbrookes Hospital, Cambridge 2011 Georgios Panos
- Thrombotic Microangiopathies; J.L. Moake, 2002, New England Journal of Medicine 247, p592 08-22-02; Massachusetts Medical Society
